Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

Obesity is a huge financial burden on our healthcare system. Over the past few decades, pre GLP-1 drugs, multiple weight loss drugs were ... and seeds–which contain fiber and aren’t absorbed before ...

Glucagon-like peptide-1 (GLP ... acting, drug-fused IgGs act as excellent peptide ferries, but they are costly because the antibodies must be extracted and modified in a laboratory before they ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation ... date that GLP-1 agonist drugs are largely safe and ...

At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients ... about ordering a cost-benefit analysis before making the commitment. Already, West Virginia ...